The way some critics see it, the risk to Allergan’s older products—from both generics and other branded competitors—“is not well captured in consensus,” Bernstein’s Ronny Gal wrote in a Friday note to clients. And “as long as downside risks are not well captured by us (and our peers) in models, it is a barrier to stock performance.”
Actavis` Viibryd (Vilazodone HCL 20Mg) Receives Supplemental Approval in USA For MDD